Tiếng Việt

Vaccine Formulation

Lab Solutions for Testing, Quality Control, and Development of Vaccines

Gọi để được báo giá
Close-up image of a virus
viral vaccines
  • Viral vaccines. The two main approaches to whole virus vaccines are:
    • Live attenuated vaccines, which use a weakened form of the virus that can still replicate without causing illness.
    • “Killed” vaccines, which use viruses that cannot replicate but still trigger an immune response since the antigens present in the viral structure are kept.
recombinant viral vector vaccines
  • Recombinant viral vector vaccines. Viral vector vaccines use an unrelated attenuated virus (adenovirus) to hijack cellular machinery and give host cells instructions to produce antigens that trigger an immune response.
     
subunits/recombinant protein vaccines
  • Subunits/Recombinant protein vaccines. Recombinant proteins vaccines or protein subunits vaccines use pieces of the pathogen produced using recombinant DNA technology.
toxoid vaccines
  • Toxoid vaccines. Toxoid vaccines are prepared from attenuated toxins secreted from bacteria. The technology is matured and vaccines of this type are used for diseases such as tetanus and diphtheria worldwide.
bioconjugate vaccines
  • Bioconjugate vaccines. Bioconjugate vaccines modify or combine two or more different vaccine components by mechanical, chemical, or biocatalytic (enzymatic) processes.
mRNA vaccines and pDNA vaccines
  • mRNA vaccines and pDNA vaccines. Nucleic acid vaccines include mRNA and pDNA (circular plasmid DNA) vaccines. These vaccines use genetic material, either RNA or DNA, to provide cells with the instructions to make an antigen. Once inside a human cell, mRNA or pDNA vaccines use the cells’ protein machinery to make the antigen that will trigger an immune response.
Available Vaccine Adjuvants
Vaccine Stabilizers and Excipients

1. Screen and Select the Adjuvant

Adjuvant screening

2. Assess Antigen-Adjuvant Interactions

Antigen and adjuvant interactions and screening.

3. Optimize Vaccine Stability

Optimizing vaccine against a number of factors

4. Filtrate for Final Concentrations

5. Freeze-Dry Final Formulations

In-Situ Particle Characterization via PAT

Differential Scanning Calorimetry (DSC) and Temperature

Karl Fischer (KF) Titration and Water Content

UV Vis Spectroscopy

Karl Fischer (KF) Titration

Meeting Vaccine Development Regulations
iC Software Suite
LabX Laboratory Software

FAQ